Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma-Reference-Cited by-同舟云学术

Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma

Published:2018-06-11 Issue:2 Volume:21 Page:197-205
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Deng L.-L.,Deng H.-B.,Lu C.-L.,Gao G.,Wang F.,Yang Y.^ORCID

Funder

Postdoctoral Scientific Research Developmental Fund of Heilongjiang Postdoctoral Program, China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s12094-018-1906-4/fulltext.html

Reference35 articles.

1. An N, Yang X. Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma. Sci Rep. 2017;7(1):11119. https://doi.org/10.1038/s41598-017-11520-6 .

2. Song Z, Yu X, Zhang Y. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biol Ther. 2017;18(11):883–7. https://doi.org/10.1080/15384047.2016.1235660 .

3. Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, et al. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer. 2016;16(1):864. https://doi.org/10.1186/s12885-016-2902-0 .

4. Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, et al. Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119–25. https://doi.org/10.1016/j.lungcan.2016.11.022 .

5. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28(5):744–52. https://doi.org/10.1200/JCO.2009.24.3030 .

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic Liver Tumors in Surgical Pathology: Impact of Contemporary Diagnostic and Therapeutic Paradigms in a Tertiary Care Center;International Journal of Surgical Pathology;2021-06-14

2. Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes;BioMed Research International;2020-12-31